Taysha Gene Therapies Reports Q3 2026 Financial Results and Clinical Trial Progress
Taysha Gene Therapies (TSHA) reported a net loss of $39.1 million for the third quarter of 2026, compared to $32.7 million in the prior-year period. Despite the increased loss, the company maintains a strong liquidity position with $422.8 million in cash and cash equivalents, which management expects will fund operations into the second half of 2028. On the clinical front, Taysha reported positive safety data for its lead candidate, TSHA-102, with 33 total patients dosed across three trials showing no severe treatment-related serious adverse events. The company is progressing through its REVEAL and ASPIRE pivotal trials and aims to submit a Biologics License Application (BLA) following interim analysis data expected in the first half of 2027.
Tickers: $TSHA
Topics: clinical trials earnings report financial results R&D expenses